Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR

FASENRA® is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma.

Discover the mechanism of action of FASENRA® (benralizumab injection)

FASENRA® has a targeted mechanism of action1*

  • Airway inflammation is an important component in the pathogenesis of asthma.
  • Eosinophils and other cell types are involved in inflammation in asthma.
about-fasenra-ADCCabout-fasenra-ADCC

Explore FASENRA®’s mechanism of action

Pharmacodynamic data

FASENRA® (benralizumab injection) demonstrated near complete reduction of blood eosinophils in the phase 3 SIROCCO trial1,2†,‡

Changes from baseline in blood eosinophil counts vs. placebo

Pharmacodynamic-data-graphPharmacodynamic-data-graph

Adapted from FASENRA® Product Monograph and Data on File.

Near complete blood eosinophil depletion was seen at the first observed time point (week 4) and sustained throughout the treatment period.1†

Maintenance of near complete eosinophil depletion was observed throughout a 56-week extension study (BORA).1†§

*Comparative clinical significance unknown.

† Clinical significance unknown.

‡ SIROCCO: 48-week, phase 3, randomized, double-blind study in patients with severe, uncontrolled asthma taking high-dose ICS + LABA. The primary efficacy (ITT) population had blood eosinophil count ≥300 cells/µL.1

§ BORA: 56-week, phase 3, uncontrolled, single-blind extension study of 440 patients with severe eosinophilic asthma who were tolerant to FASENRA®.1

ITT: intent-to-treat; LS: least squares.

References:

  1. FASENRA® Product Monograph, AstraZeneca Canada Inc.
  2. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127 (incl. supplement).